Article: Tips for successful editing in T cells
Horizon article on the recipe for success for CRISPR editing in T cells.
List view / Grid view
Horizon article on the recipe for success for CRISPR editing in T cells.
This article explains how to plan a gene-editing experiment. How to choose your biological system and what reagents to get for your experimental aim.
The Octet® systems provide broad applications in high throughput to help bispecific and multi-specific antibody discovery.
This application note by ForteBio explores antibody fragment molecule (Fab) for process development and quality control.
In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology enabling the identification of novel cancer biomarkers.
Modify the genome and modulate expression of genes within human iPS cells with Dharmacon™ Edit-R CRISPR reagents.
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
So you have performed your screen. What’s next? This guide is focused on how biochemical assays are used for characterising and prioritising compounds.
4 September 2020 | By Horizon Discovery
During this on-demand webinar we present data showing how Horizon’s CRISPRsc screening platform offers a streamlined approach to elucidating valuable and intriguing biological information that is critical to resolving complex biological questions.
Scientists observed that different cancers undergo the same genetic mutations at similar stages of evolution, the findings could become part of an ‘evolutionary rule book’ which would theoretically enable the prediction and prevention of cancer’s next evolutionary move.
The global network of centers will investigate where pathogens emerge and how they adapt to cause disease in humans, in the hopes of increasing our preparedness for future disease outbreaks.
Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.